Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00303303 · ClinicalTrials.gov registry record · Phase 4
The Efficacy of Crotaline Fab Antivenom for Copperhead Snake Envenomations
A Phase 4 study, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- Phase 4
- Development phase
- 13
- Enrollment target
NCT00303303 is a Phase 4 study that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 13 participants.
The verdict
NCT00303303, a Phase 4 study, was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 13 participants
- Enrollment target
Study Summary
Most patients bitten by copperhead snakes do not currently receive antivenom. Some snakebite victims have long term problems with the function of the limb that was bitten. This study will determine whether early administration of antivenom to patients with mild to moderate copperhead snakebites reduces long-term complications.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Crotaline Polyvalent Immune Fab (ovine) (active initial and maintenance therapy)
- BIOLOGICAL Crotaline Immune Fab (ovine) (active initial therapy; placebo maintenance therapy)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2005-04 |
| Est. Completion | 2008-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00303303
The ClinicalTrials.gov registry entry for NCT00303303 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00303303 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00303303 about?
NCT00303303 is a clinical study titled "The Efficacy of Crotaline Fab Antivenom for Copperhead Snake Envenomations". Most patients bitten by copperhead snakes do not currently receive antivenom. Some snakebite victims have long term problems with the function of the limb that was bitten. This study will determine whether early administration of antivenom to patients with mild to moderate copperhead snakebites redu...
What is the current status of trial NCT00303303?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 13 participants. The study started on 2005-04. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00303303?
The interventions under investigation include: Placebo (BIOLOGICAL), Crotaline Polyvalent Immune Fab (ovine) (active initial and maintenance therapy) (BIOLOGICAL), Crotaline Immune Fab (ovine) (active initial therapy; placebo maintenance therapy) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00303303?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.